Director, Translational Pathology Cancer Biomarker Development
Company: AstraZeneca
Location: Montgomery Village
Posted on: June 26, 2025
|
|
Job Description:
We are seeking an MD Anatomical Pathologist to lead the
implementation of biomarker strategies and provide pathology
expertisefor our early oncology research and development team
within the Cancer Biomarker Development group. Our pathology team
plays a crucial role in supporting AstraZeneca’s translational
medicine strategy for an innovative early oncology pipeline that
includes Antibody-Drug Conjugates (ADCs), Radio-conjugates, T-cell
engagers, CAR-T therapies, bispecific antibodies, and small
molecules. In this role, based in Gaithersburg, MD, you will
collaborate with a diverse team of pathologists, image analysts,
bioinformaticians, translational scientists, biologists, and
oncologists. This unique opportunity allows you to contribute to
the development of new biomarkers, enabling indication selection,
early assessment of biological activity, and optimal patient
stratification. Your efforts will significantly enhance the
probability of success for AstraZenecas oncology pipeline.
Responsibilities: Support the designand implementation of
tissue-based biomarker strategies for early and late oncology
assets, spanning Ph1 to Ph3 clinical studies. Lead the design,
development, and validationof immunohistochemistryand multiplex
assays, including the creation of robustscoring/quantitation
methods. Deliver target expression data to inform indication
selection and identifyoptimal patient populations. Facilitate
informed biomarker selection by applying knowledge of the
mechanisms of action, pharmacodynamics, and pharmacokinetics of the
therapeutic agents. Assist in the development of Clinical Trial
Prototype IHC assays and Companion Diagnostics (CDxs) in
collaboration with diagnostic companies and CROs. Contribute
advanced knowledge in cancer diagnosis and classification to the
design of clinical study protocols, laboratory manuals, and various
regulatory documents. Providehistopathological guidance to
Computational Pathology, Translational Proteomics, Genomics,
Discovery, and other Early Oncology teams to ensure the delivery of
high-quality and robust data across the asset portfolio. Essential
requirements: M.D. from an accredited medical university and board
certification in anatomical pathology by a world-recognized
examination board. >7 years of experience in biopharmaceutical
and/or academic settings, including at least 3 years of experience
in translational research and oncology biomarker analysis. A strong
publication record is highly desirable. Diagnostic experience over
a wide range of organs and disease entities. Effective time
management and prioritization for various tasks across multiple
projects at different stages. Excellent communication skills and
strong collaboration skills to cooperate with experts from various
technical and scientific backgrounds. Team player, who enjoys
working in an international team. Additional qualifications
(non-essential): Strong knowledge/experience intumor biologyand
oncology therapy landscape. Strong knowledge in drug
development,digital image analysis, CDx development (from target
identification to post-marketing approval), and
immunohistochemistry assay optimization. Experience in spatial
analytics, multiplex IHC technologies, and AI-assisted image
analysis. Experience in the analysis of preclinical models (cell
lines, xenografts), and orthogonal methods of target expression
measurement (proteomics, FACS, RNA sequencing). The annual base pay
for this position ranges from 241613.6 - 362420.4 Base pay offered
may vary depending on multiple individualized factors, including
market location, job-related knowledge, skills, and experience. In
addition, our positions offer a short-term incentive bonus
opportunity; eligibility to participate in our equity-based
long-term incentive program (salaried roles), to receive a
retirement contribution (hourly roles), and commission payment
eligibility (sales roles). Benefits offered included a qualified
retirement program [401(k) plan]; paid vacation and holidays; paid
leaves; and, health benefits including medical, prescription drug,
dental, and vision coverage in accordance with the terms and
conditions of the applicable plans. Additional details of
participation in these benefit plans will be provided if an
employee receives an offer of employment. If hired, employee will
be in an “at-will position” and the Company reserves the right to
modify base pay (as well as any other discretionary payment or
compensation program) at any time, including for reasons related to
individual performance, Company or individual department/team
performance, and market factors. Date Posted 06-Jun-2025 Closing
Date 05-Jun-2025Our mission is to build an inclusive and equitable
environment. We want people to feel they belong at AstraZeneca and
Alexion, starting with our recruitment process. We welcome and
consider applications from all qualified candidates, regardless of
characteristics. We offer reasonable adjustments/accommodations to
help all candidates to perform at their best
Keywords: AstraZeneca, Frederick , Director, Translational Pathology Cancer Biomarker Development, Science, Research & Development , Montgomery Village, Maryland